What did @orianna_williams actually say?
She said she lost 28 pounds over 16 weeks on compounded tirzepatide, paying $270 for three months, which works out to roughly $22 per injection. She's been taking 2.5 mg (25 units) and is now moving herself up to 3.5 mg (35 units) because she hit a plateau. She also linked to the peptide vendor in her bio.
That's the summary. But several things in this video deserve a harder look, starting with where she's getting this medication and who, if anyone, is supervising her dose escalation.
Does the science back this up?
The weight loss numbers are plausible. The self-directed dose escalation is a real concern, and the compounded peptide market she's shopping in is legally and medically complicated.
Tirzepatide's clinical data is genuinely impressive. The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) showed participants lost up to 20.9% of body weight over 72 weeks on 15 mg doses. Twenty-eight pounds in 16 weeks at 2.5 mg is on the higher end of what early-phase data would predict, but it's not implausible for someone with a favorable metabolic response, particularly if they also changed their eating habits.
The dose jump she's describing, from 2.5 mg to 3.5 mg, does not follow FDA-approved titration schedules, which move in 2.5 mg increments every four weeks. She's essentially inventing a dose. Whether that's dangerous depends on the individual, but it's not evidence-based, and nobody in this video appears to be supervising her.
What did they get wrong (or right)?
She got the weight loss story right in terms of biological plausibility. Tirzepatide acts on both GIP and GLP-1 receptors, and early dose response can be significant for some people. Credit where it's due.
What she got wrong, or at least glossed over, matters more. First, the vendor she's promoting, Paramount Peptides, sells what are marketed as research-use peptides. These products are not FDA-approved formulations. Compounded tirzepatide from a licensed 503A or 503B pharmacy is a different regulatory category than a peptide vendor selling products online. Conflating the two is misleading to her 99,000 viewers.
Second, "I haven't had any symptoms" is not a green light to self-escalate your dose. Pancreatitis, gallbladder disease, and delayed gastric emptying can emerge at higher doses without warning signs at lower ones. A 2023 FDA advisory flagged compounded semaglutide and tirzepatide products for quality concerns, and similar warnings extend to unregulated peptide suppliers.
Third, she's recommending a specific dosing unit conversion (25 units equals 2.5 mg) to a mass audience. That math depends entirely on the concentration of whatever she received, and concentrations vary between vendors. Dosing errors with injectable peptides can cause hypoglycemia and other adverse events.
What should you actually know?
Compounded tirzepatide from a licensed pharmacy is not the same product as tirzepatide from a peptide vendor, and both are different from FDA-approved Zepbound or Mounjaro. The FDA placed tirzepatide on its shortage list, which opened a window for licensed compounders, but that window has been narrowing. The regulatory status of any given vendor changes frequently.
If you're considering tirzepatide for weight loss, the access and cost barriers are real. Zepbound listed at around $1,000 per month without insurance, so the appeal of $270 for three months is obvious. But the risk of buying from an unregulated vendor, including unknown purity, incorrect concentration, and zero medical oversight, is also real.
A telehealth provider can prescribe compounded tirzepatide from a licensed 503A pharmacy and actually monitor your response, adjust your dose based on labs and symptoms, and catch problems before they become emergencies. That's not a plug. That's just what supervised care looks like compared to what's in this video.
Is this video dangerous?
Potentially, yes. The combination of a specific vendor link, unit-to-milligram conversion instructions, and self-directed dose escalation advice reaches nearly 100,000 people. Most of them have no idea whether the concentration math applies to whatever they might order. The Endocrine Society's clinical practice guidelines (Garvey et al., 2022, Journal of Clinical Endocrinology and Metabolism) specifically recommend medical supervision for GLP-1 and dual agonist therapy, including titration decisions. This video is the opposite of that.